This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merrimack Pharmaceuticals Initiates Cross-Tumor Study To Investigate Potential Predictive Response Markers For A Developmental Nanotherapeutic Chemotherapy

CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study is designed to identify predictive biomarkers associated with the novel compound MM-398 in advanced colorectal, lung and triple-negative breast cancers. Specifically, it aims to establish the feasibility of collecting specialized magnetic resonance-based images (MRI) and tissue-based biomarkers for the purpose of estimating drug delivery to the tumor and patient response to MM-398.

A stable, nanotherapeutic encapsulation of the chemotherapy irinotecan, MM-398 is designed to optimize the delivery of irinotecan by increasing levels of the drug deposited in the tumor, extending circulation and thereby enabling preferential activation of the therapy within the tumor. Preclinical research has shown that the length of time MM-398, specifically the active component, SN38, remains within tumors directly correlates with tumor response. Another key to MM-398's activity may be the number of macrophages within a tumor, which have been shown to preferentially internalize liposomes and release their contents.

"Our research indicates tumor micro-environments across these clinical indications allow for the deposition of large particles, such as nanotherapeutics. They also have high levels of tumor-associated macrophages, which means MM-398 can be broken down and release increased levels of chemotherapy to the adjacent cancer cells," said Ulrik Nielsen, Co-Founder and Chief Scientific Officer of Merrimack. "We believe this study is the first of its kind to combine the use of both imaging and biomarker diagnostic approaches and we hope that the insights we gain from this study will help to predict response to MM-398 in these hard-to-treat tumors."

The cross indication translational study will focus on patients that have progressed following standard of care therapy for colorectal, lung and triple-negative breast cancers. The study is taking place at Scottsdale Healthcare Medical Center in Arizona.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs